Our data showed that patients with metastatic colorectal cancer had higher serum levels of hepcidin than the controls, and patients with circulating levels of hepcidin greater than 40 ng/mL had a reduced overall survival as compared to those with values lower than 40 ng/mL. Here, HAMP is linked to metastatic colorectal cancer.